Maintenance Regimens for Multiple Myeloma
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

ECOG Trial Outcomes in Smoldering Myeloma
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering multiple myeloma (MM). <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Difference in Daratumumab from Isatuximab
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment ... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Progression-Free Survival in MM
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in patients with relapsed/refractory multip... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Update on FORTE Trial Data
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes the updated FORTE trial data in multi... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts